Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Inclusion Criteria: * Considered transplant eligible * Pathologically confirmed diagnosis of multiple myeloma who are transplant eligible and have received any prior induction therapy (with or without maintenance) * Measurable MRD in bone marrow within 28 days prior to registration (MPF method) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2 at registration * Absolute neutrophil count (ANC) \>= 1,000 cell/mm\^3 without growth factor support, obtained =\< 14 days prior to registration * Platelets \>= 50,000 cells/mm\^3 for patients who have bone marrow plasmacytosis \< 50% or \>= 30,000 cells/mm\^3 for patients who have bone marrow plasmacytosis of \>= 50%, obtained =\< 14 days prior to registration * Calculated or measured creatinine clearance \>= 30 ml/min, obtained =\< 14 days prior to registration * Total bilirubin =\< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome, in which case the direct bilirubin must be =\< 1.5 X ULN, obtained =\< 14 days prior to registration * Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =\< 3 x ULN, obtained =\< 14 days prior to registration * Prothrombin time (PT)/international normalized ratio (INR) =\< 1.5 X ULN, obtained =\< 14 days prior to registration * Negative urine or serum pregnancy test for women of childbearing potential * NOTE: females of reproductive potential must adh…